Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis

Sadettin Uslu, Semih Gülle, Gercek Sen, Sedat Capar, Soner Senel, Ediz Dalkılıc, Servet Akar, Süleyman Serdar Koca, Abdurrahman Tufan, Ayten Yazici, Sema Yilmaz, Nevsun Inanc, Merih Birlik, Dilek Solmaz, Ayse Cefle, Berna Goker, Haner Direskeneli, Servet Yolbas, Niels Steen Krogh, Neslihan Yilmaz, S · 2024

Read Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis by Sadettin Uslu, Semih Gülle, Gercek Sen, Sedat Capar, Soner Senel, Ediz Dalkılıc, Servet Akar, Süleyman Serdar Koca, Abdurrahman Tufan, Ayten Yazici, Sema Yilmaz, Nevsun Inanc, Merih Birlik, Dilek Solmaz, Ayse Cefle, Berna Goker, Haner Direskeneli, Servet Yolbas, Niels Steen Krogh, Neslihan Yilmaz, S (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11642210.txt.

Description

Sadettin Uslu and co-authors report a 2024 study of a biosimilar drug in spine arthritis. Ankylosing spondylitis stiffens the spine through inflammation. CT-P13 is a biosimilar copy of infliximab, a proven antibody drug. The team asks how well it works and how long patients stay on it in real practice. Data come from a national Turkish registry of biologic drugs, covering 2014 to 2021. Patients split into first-line users and those on it after other biologics.

Drug persistence, safety, and effect are tracked in both groups. Registry data answer questions trials cannot: what happens over years, in mixed patients, after switches. Rheumatologists get persistence numbers that guide counseling when a cheaper biosimilar is offered. Payers care too, since biosimilars cut costs only if patients stay on them. First-versus-later line splits show whether prior failures dim the copy's value.

Catalog record

CREATORSadettin Uslu, Semih Gülle, Gercek Sen, Sedat Capar, Soner Senel, Ediz Dalkılıc, Servet Akar, Süleyman Serdar Koca, Abdurrahman Tufan, Ayten Yazici, Sema Yilmaz, Nevsun Inanc, Merih Birlik, Dilek Solmaz, Ayse Cefle, Berna Goker, Haner Direskeneli, Servet Yolbas, Niels Steen Krogh, Neslihan Yilmaz, S
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11642210

Browse the full library · About the Tower of Babel